Atara Biotherapeutics, Inc. (ATRA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Atara Biotherapeutics, Inc. (ATRA) closed at USD 9.65 on 2026-10-15, a change of -31.4 % over the past year, with a market capitalization of USD 92.15M.

Atara Biotherapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Atara Biotherapeutics, Inc. key figures

Previous close

USD 9.65 (2026-10-15)

1-year change

-31.4 %

Market cap

USD 92.15M

Enterprise value

USD 92.15M

P/E ratio (trailing)

-7.06

P/E ratio (forward)

5.94

EPS (trailing)

-1.30

EPS (forward)

1.55

PEG ratio

n/a

Price to book

-2.34

Revenue growth

-96.4 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.91

Employees

10

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Atara Biotherapeutics, Inc. and compare it with other stocks.